Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC

Patients will be randomized to 2 groups

Inclusion criteria

• 18~70 years
• Patients who were diagnosed by the histologic, cytologic diagnosis of IIIb-IV non-small cell lung cancer
• Presence of at least one index lesion measurable by CT scan or MRI
• Ecog0-1
• Expected life time longer than 12 weeks
• Normal laboratory values:

• leucocyte ≥ 4×109/L
• neutrophil ≥ 1.5×109/L
• platelet ≥ 100×109/L
• Hemoglobin ≥ 10g/L
• ALT and
• AST ≤ 2.5×ULN (≤ 5×ULN if liver metastasis)
• Signed written informed consent

Exclusion criteria

• Patients have used drugs according to protocol
• Patients were allergic to pemetrexed or cisplatin
• Patients received radiotherapy or other biological treatment 4 weeks before the trial
• Uncontrolled hydrothorax or hydropericardium
• neuropathy toxicity ≥ CTC 3
• Severe symptomatic heart disease
• Active upper gastrointestinal ulcer or digestive disfunction
• Severe infection or metabolic disfunction
• Patients with other malignant tumor
• Uncontrolled brain metastases
• Patients have accepted other clinical trials
• Female patients during their pregnant and lactation period, or patients without contraception